BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Steinmeier honours Italian 'guest workers' who rebuilt German economy- I spent the last year transforming my life. Becoming a Rockette for a day made me confront a fear I couldn't shake.
- Why don’t humans have hair all over their bodies? A biologist explains our lack of fur
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- The Way to Monetary Health: Individual budget Change
- Putin says Russian forces will seize capital of Zaporizhzhya
- Language Learning Applications for Voyagers
- Putting resources into Yourself: Self-awareness Techniques
- 21 Things You Ought to Never Tell Your Childless Companion
